Global Hotspots and Prospects of I-131 Therapy in Thyroid Carcinoma via Bibliometric Analysis

References

• He W, Qi B, Zhou Q, et al. Key genes and pathways in thyroid cancer based on gene set enrichment analysis. Oncol Rep. 2013;30(3):1391–1397. doi:10.3892/or.2013.2557
   PubMed Web of Science ®Google Scholar
• Tsimbas K, Turek M, Christensen N, Vail DM, Forrest L. Short survival time following palliative-intent hypofractionated radiotherapy for non-resectable canine thyroid carcinoma: a retrospective analysis of 20 dogs. Vet Radiol Ultrasound. 2019;60(1):93–99.
   PubMed Web of Science ®Google Scholar
• Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol. 2011;2011:542358.
   PubMedGoogle Scholar
• Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the National Cancer Data Base. Cancer. 2017;123(9):1653–1661.
   PubMed Web of Science ®Google Scholar
• Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453–464.
   PubMed Web of Science ®Google Scholar
• American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C; Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
   PubMed Web of Science ®Google Scholar
• Scheffel RS, Zanella AB, Dora JM, Maia AL. Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma. Thyroid. 2016;26(11):1623–1629.
   PubMed Web of Science ®Google Scholar
• Brierley J, Tsang R, Panzarella T, Bana N. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf). 2005;63(4):418–427.
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
   PubMed Web of Science ®Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803. doi:10.1530/eje.1.02158
   PubMed Web of Science ®Google Scholar
• Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–1959.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–1463.
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366(18):1663–1673.
   PubMed Web of Science ®Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–2899.
   PubMed Web of Science ®Google Scholar
• Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–1685.
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297–306.
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–428.
   PubMed Web of Science ®Google Scholar
• Mourao GF, Rosario PW, Calsolari MR. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation. Endocr Relat Cancer. 2016;23(1):47–52.
   PubMed Web of Science ®Google Scholar
• Shang L, Fang S, Zhang P, et al. Impact factors for the outcome of the first (131)I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy. Ann Nucl Med. 2019;33(3):177–183.
   PubMed Web of Science ®Google Scholar
• Wu X, Gu H, Gao Y, Li B, Fan R. Clinical outcomes and prognostic factors of radioiodine ablation therapy for lymph node metastases from papillary thyroid carcinoma. Nucl Med Commun. 2018;39(1):22–27.
   PubMed Web of Science ®Google Scholar
• Rosario PW, Calsolari MR. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Thyroid. 2014;24(5):826–831.
   PubMed Web of Science ®Google Scholar
• Ge J, Wang J, Wang H, et al. The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer. J Cancer. 2020;11(4):932–939.
   PubMed Web of Science ®Google Scholar
• Lupoli R, Cacciapuoti M, Tortora A, et al. Clinical outcome in differentiated thyroid carcinoma and microcarcinoma. Int J Surg. 2014;12(Suppl 1):S148–51.
   PubMed Web of Science ®Google Scholar
• Hung MC, Wu HS, Kao CH, Chen WK, Changlai SP. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res. 2003;29(2):169–175.
   PubMed Web of Science ®Google Scholar
• Giovanella L, Scappaticcio L. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach. Q J Nucl Med Mol Imaging. 2019;63:229–234.
   PubMed Web of Science ®Google Scholar
• Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. Thyroid. 2009;19(12):1381–1391.
   PubMed Web of Science ®Google Scholar
• Kairemo K, Kangasmaki A, Bom HS. Comparison of I-131 biokinetics after recombinant human TSH stimulation and thyroid hormone withdrawal measured by external detector in patients with differentiated thyroid cancer. Chonnam Med J. 2019;55(1):20–24.
   PubMedGoogle Scholar
• Kasner DL, Spieth ME, Starkman ME, Zdor-North D. Thyroid carcinoma: iodine-131-negative whole-body scan reverses to positive after a combination of thyrogen stimulation and withdrawal. Clin Nucl Med. 2002;27(11):772–780.
   PubMed Web of Science ®Google Scholar
• Zilioli V, Peli A, Panarotto MB, et al. Differentiated thyroid carcinoma: incremental diagnostic value of (131)I SPECT/CT over planar whole body scan after radioiodine therapy. Endocrine. 2017;56(3):551–559.
   PubMed Web of Science ®Google Scholar
• Raruenrom Y, Sawangsri K, Somboonporn C, Theerakulpisut D, Wongsurawat N, Ratanaanekchai T. An impact of microscopic positive margin on incomplete response after I-131 treatment in differentiated thyroid cancer. Ann Nucl Med. 2020;34(7):453–459.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–1139.
   PubMed Web of Science ®Google Scholar
• Zupunski L, Ostroumova E, Drozdovitch V, et al. Thyroid cancer after exposure to radioiodine in childhood and adolescence: (131) I-related risk and the role of selected host and environmental factors. Cancers (Basel). 2019;11:10.
   Web of Science ®Google Scholar
• Chen MK, Cheng DW. What is the role of dosimetry in patients with advanced thyroid cancer? Curr Opin Oncol. 2015;27(1):33–37.
   PubMed Web of Science ®Google Scholar
• Fish SA, Basu S, Alavi A, Mandel SJ. Comparison of efficacy of 2220 MBq versus 3700 MBq I-131 for ablation of thyroid remnant in patients with differentiated thyroid cancer. Quart J Nucl Med Mol Imaging. 2010;54(5):560–563.
   PubMed Web of Science ®Google Scholar
• Broer SL, Broekmans FJM, Laven JSE, et al. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20:688–701.
   PubMed Web of Science ®Google Scholar
• Qian ZJ, Jin MC, Meister KD, Megwalu UC. Pediatric thyroid cancer incidence and mortality trends in the United States, 1973-2013. JAMA Otolaryngol Head Neck Surg. 2019;145(7):617–623.
   PubMed Web of Science ®Google Scholar
• van Velsen EFS, Stegenga MT, van Kemenade FJ, et al. Comparing the prognostic value of the Eighth Edition of the American Joint Committee on Cancer/Tumor Node Metastasis Staging System Between Papillary and Follicular Thyroid Cancer. Thyroid. 2018;28(8):976–981.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Florou P, Bosdou JK, et al. Decline in anti-Müllerian hormone concentrations following radioactive iodine treatment in women with differentiated thyroid cancer: a systematic review and meta-analysis. Maturitas. 2021;148:40–45.
   PubMed Web of Science ®Google Scholar
• Piek MW, Postma EL, van Leeuwaarde R, et al. The effect of radioactive iodine therapy on ovarian function and fertility in female thyroid cancer patients: a systematic review and meta-analysis. Thyroid. 2021;31(4):658–668.
   PubMed Web of Science ®Google Scholar
• Nies M, Cantineau AEP, Arts EGJM, et al. Long-term effects of radioiodine treatment on female fertility in survivors of childhood differentiated thyroid carcinoma. Thyroid. 2020;30(8):1169–1176.
   PubMed Web of Science ®Google Scholar
• Bykov Vladimir JN, Eriksson Sofi E, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18:89–102.
   PubMed Web of Science ®Google Scholar
• Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer. 2018;18(2):89–102.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–690.
   PubMed Web of Science ®Google Scholar
• Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol. 2016;16(12):741–750.
   PubMed Web of Science ®Google Scholar
• Arena A, Stigliano A, Belcastro E, et al. p53 activation effect in the balance of T regulatory and effector cell subsets in patients with thyroid cancer and autoimmunity. Front Immunol. 2021;12:728381.
   PubMed Web of Science ®Google Scholar
• Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–135.
   PubMedGoogle Scholar
• Kwak JJ, Altoos R, Jensen A, Altoos B, McDermott MT. Increased risk of radioiodine treatment failure associated with graves disease refractory to methimazole. Endocr Pract. 2020;26(11):1312–1319.
   PubMed Web of Science ®Google Scholar
• Namwongprom S, Dejkhamron P, Unachak K. Success rate of radioactive iodine treatment for children and adolescent with hyperthyroidism. J Endocrinol Invest. 2021;44(3):541–545.
   PubMed Web of Science ®Google Scholar
• Kaplowitz PB, Jiang J, Vaidyanathan P. Radioactive iodine therapy for pediatric Graves’ disease: a single-center experience over a 10-year period. J Pediatr Endocrinol Metab. 2020;33(3):383–389.
   PubMed Web of Science ®Google Scholar